Quantcast

Latest metronidazole Stories

2010-09-14 08:30:00

SAN DIEGO, Sept. 14 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that new data from its North American and European fidaxomicin Phase 3 clinical trials in patients with Clostridium difficile infection (CDI) was presented at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Boston. (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)...

2010-08-19 07:00:00

SAN DIEGO, Aug. 19 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the European Medicines Agency (EMA) has accepted for review Optimer's Marketing Authorization Application (MAA) for fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI in the European Union (EU). Optimer announced the submission of its MAA for fidaxomicin to the EMA on August 2, 2010. (Logo:...

2010-07-29 07:00:00

SAN DIEGO, July 29 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that it has submitted a Marketing Authorization Application (MAA) for fidaxomicin to the European Medicines Agency (EMA) under the European Union's Centralized Procedure. Optimer is seeking approval to market fidaxomicin for the treatment of patients with Clostridium difficile infection (CDI). (Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO) (Logo:...

2010-05-17 15:52:00

SCHAUMBURG, Ill., May 17 /PRNewswire/ -- Sagent Pharmaceuticals, Inc. today announced the voluntary nationwide recall of all lots of metronidazole injection, USP 500mg / 100mL (NDC number 25021-131-82) manufactured by Claris Lifesciences and distributed by Sagent. The lot numbers being recalled are: A090742, A090743, A090744, A090745, A090746, A090769, A090770, A090771, A090772, A090773, A090774, A090775, A090776, A090968, A091014, A000013, A000016 and A000019, which were distributed to...

2010-05-04 14:15:00

SAN DIEGO, May 4 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced the presentation of new data from its second fidaxomicin Phase 3 clinical study in patients with Clostridium difficile infection (CDI). The data, presented by Stuart Johnson, M.D. during an oral session at the annual meeting of Digestive Disease Week (DDW) in New Orleans, indicated that treatment with fidaxomicin significantly improved the recurrence rate and global cure rate in CDI patients...

2010-04-14 08:30:00

BARRINGTON, Ill., April 14 /PRNewswire/ -- From job interviews to first dates, creating a positive and lasting first impression often goes a long way. For women with symptoms of the common skin condition rosacea, just how much does the appearance of their skin affect how people perceive them? A unique digital perception survey, developed in partnership with the National Rosacea Society (NRS) and Galderma Laboratories, contrasted images of women with signs of mild to moderate...

2010-03-22 08:00:00

FORT WORTH, Texas, March 22 /PRNewswire/ -- Galderma Laboratories, L.P. today announced the U.S. Food and Drug Administration (FDA) approval of Differin® (adapalene) Lotion, 0.1%, the first-ever lotion formulation of the well-tolerated retinoid adapalene, for the treatment of acne. Differin Lotion, 0.1% will be available by prescription in April 2010. Differin Lotion, 0.1% is formulated for tolerable efficacy, spreads easily and is available in a convenient, easy-to-use...

2009-09-15 12:45:00

SAN DIEGO, Sept. 15 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that new data highlighting fidaxomicin's (OPT-80) lower CDI recurrence rates and reduced risk of vancomycin-resistant enterococci (VRE) acquisition from Optimer's North American phase 3 study were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. (Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)...

2009-09-02 07:00:00

MALVERN, Penn. and WALTHAM, Mass., Sept. 2 /PRNewswire/ -- Arlington Medical Resources (AMR) and Decision Resources find that relapse or recurrence of infections is the most challenging aspect of treating Clostridium difficile infections in the hospital setting. Surveyed infectious disease specialists emphasize the need for new agents that have lower relapse rates than the current standard-of-care. Currently, clinicians have limited treatment options for patients with this infection; oral...

2009-07-08 11:17:55

Antimicrobial treatments for bacterial vaginosis (BV) are effective, but taking lactobacillus tablets alongside metronidazole antibiotic therapy increases effectiveness over taking this antibiotic alone, according to a Cochrane Systematic Review. The researchers also concluded that intravaginal lactobacillus was as effective as oral metronidazole, although they did note unexplained drop-outs from the trials.BV is a very common vaginal infection. Traditionally, antibiotics in tablet or gel...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'